| Objective: To investigate the inflammatory-immune regulatory effects of Xingbei Zhike Granules combine with beclomethasone dipropionate on children with acute exacerbation of bronchial asthma. Method: Using random number table, 106 children with acute exacerbation of bronchial asthma were divided into control group (n=53, treated with inhaled beclomethasone dipropionate nebulization) and study group (n=53, treated with Xingbei Zhike Granules combined with inhaled beclomethasone dipropionate nebulization). 2 weeks after treatment, the clinical symptom relief time, inflammatory factors [interleukin (IL) -6, tumor necrosis factor-α (TNF-α), IL-10], and immune function indicators [immunoglobulin (Ig) A, IgG, IgM, IgE, and T lymphocyte subsets] between the two groups were compared, and the occurrence of adverse reactions between the two groups were observe. Result: The clinical symptoms relief time such as cough, shortness of breath and wheezing in the study group were shorter than those in the control group (P<0.05). CD3+, CD4+, IL-10 and CD4+/CD8+in the study group after treatment were higher than those in the control group, while IL-6, CD8+ and TNF-α were lower than those in the control group (P<0.05). IgA, IgG and IgM levels in the study group after treatment were higher than those in the control group, while IgE levels were lower than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The combination of Xingbei Zhike Granules and beclomethasone dipropionate can shorten the symptom relief time in children with acute exacerbation of bronchial asthma, and has good medication safety, which is related to reducing the level of inflammatory factors and improving immune function. |
